High Growth Tech Stocks in Australia for October 2024
As the Australian market experiences a flat trading day with the ASX200 closing down slightly at 8,214 points, investors are increasingly turning their attention to sectors like Energy and Health Care, which have shown resilience amid broader economic uncertainties. In this environment of fluctuating market sentiment and renewed concerns about global economic growth, identifying high-growth tech stocks in Australia requires a focus on companies that demonstrate strong fundamentals and adaptability to changing conditions.
Top 10 High Growth Tech Companies In Australia
Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
Clinuvel Pharmaceuticals | 22.32% | 27.42% | ★★★★★★ |
Adherium | 86.80% | 73.66% | ★★★★★★ |
ImExHS | 20.47% | 111.20% | ★★★★★★ |
Telix Pharmaceuticals | 20.10% | 38.31% | ★★★★★★ |
DUG Technology | 10.79% | 31.83% | ★★★★★☆ |
AVA Risk Group | 32.56% | 118.83% | ★★★★★★ |
Careteq | 37.17% | 126.21% | ★★★★★☆ |
Pointerra | 56.62% | 126.45% | ★★★★★★ |
Wrkr | 36.31% | 100.29% | ★★★★★★ |
Adveritas | 57.98% | 144.21% | ★★★★★★ |
Click here to see the full list of 64 stocks from our ASX High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Pro Medicus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$19.46 billion.
Operations: Pro Medicus generates revenue primarily through the production of integrated software applications for the healthcare industry, amounting to A$161.50 million. The company focuses on providing advanced imaging and radiology information system software services to a diverse clientele in multiple regions, including Australia, North America, and Europe.
Pro Medicus, a trailblazer in healthcare imaging software, has demonstrated robust financial health and growth prospects. In the fiscal year ending June 2024, the company reported a significant revenue jump to AUD 166.33 million from AUD 127.33 million previously, underscoring an impressive growth trajectory with earnings surging by 36.5% over the past year—outpacing the industry average of 15.4%. This performance is bolstered by strategic R&D investments which have consistently aligned with revenue growth; last year alone, R&D expenses were notably high as a percentage of revenue, ensuring continuous innovation and enhancement of their offerings. Looking ahead, Pro Medicus appears well-positioned for sustained growth with projected annual earnings increases of 18.9%, surpassing broader Australian market expectations (12.2%). The company also raised its dividend payout to shareholders significantly by 33%, reflecting confidence in ongoing profitability and cash flow positivity—an attractive indicator for potential investors seeking companies with forward-thinking management and solid financial foundations in the dynamic tech landscape.
Delve into the full analysis health report here for a deeper understanding of Pro Medicus.
Evaluate Pro Medicus' historical performance by accessing our past performance report.
WiseTech Global
Simply Wall St Growth Rating: ★★★★★☆
Overview: WiseTech Global Limited develops and provides software solutions for the logistics execution industry across various regions, including the Americas, Asia Pacific, Europe, the Middle East, and Africa, with a market cap of A$44.01 billion.
Operations: WiseTech Global Limited primarily generates revenue through its Internet Software & Services segment, which accounts for A$1.04 billion. The company focuses on providing software solutions tailored to the logistics execution industry across multiple global regions.
WiseTech Global's recent performance underscores its robust position in the tech sector, with a revenue surge to AUD 1.04 billion, up from AUD 816.8 million last year, and net income increasing to AUD 262.8 million. This growth is supported by a strategic focus on R&D, which constituted 19.2% of their revenue, fostering innovation that keeps them ahead in logistics software solutions. The company's forward-looking stance is evident from their projected revenue growth of 25%-30% for FY2025 and a dividend increase reflecting confidence in sustained profitability. Recent executive shifts aim to strengthen governance as they gear up for future challenges and opportunities in global tech landscapes.
Xero
Simply Wall St Growth Rating: ★★★★★☆
Overview: Xero Limited is a software as a service company offering online business solutions for small businesses and their advisors across Australia, New Zealand, and internationally, with a market capitalization of A$22.86 billion.
Operations: Xero generates revenue primarily through providing online solutions for small businesses and their advisors, amounting to NZ$1.71 billion. The company operates in Australia, New Zealand, and internationally, focusing on software as a service offerings.
Xero's trajectory in the high-growth tech landscape of Australia is marked by robust projected earnings growth of 24.1% annually, outpacing the Australian market forecast of 12.2%. This financial vigor is complemented by a strategic emphasis on R&D, which has recently constituted 19.2% of revenue, fueling innovations that keep Xero competitive in software solutions for small businesses. Recent launches like Xero Inventory Plus highlight their commitment to enhancing operational efficiencies for their clients, integrating with major platforms such as Amazon's FBA and Shopify to streamline inventory management across sales channels. The departure of CFO Kirsty Godfrey-Billy signals upcoming executive shifts that could influence future strategies as Xero continues to expand its global footprint and product offerings.
Navigate through the intricacies of Xero with our comprehensive health report here.
Assess Xero's past performance with our detailed historical performance reports.
Taking Advantage
Take a closer look at our ASX High Growth Tech and AI Stocks list of 64 companies by clicking here.
Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Looking For Alternative Opportunities?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:PME ASX:WTC and ASX:XRO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]